Acadia Pharmaceuticals shares hit 52-week high of $29.81
Stock reaches peak after recent gains, reflecting investor optimism amid sector momentum.
Acadia Pharmaceuticals Inc. shares reached a 52-week high of $29.81 on Friday, extending a recent rally in the biotech sector.
The milestone comes amid broader strength in healthcare equities, with investors focusing on pipeline progress and earnings momentum in the pharmaceutical industry. Acadia, which develops treatments for central nervous system disorders, has seen its stock gain traction following positive clinical updates and analyst upgrades.
Trading volume spiked as the shares neared the peak, indicating heightened market interest. The company’s market capitalization now stands near $4.2 billion, reflecting the valuation at the intraday high.
The stock’s performance aligns with a broader trend of biotech outperformance in 2024, as investors weigh regulatory developments and potential commercialization timelines for key pipeline assets. Acadia’s lead drug, Nuplazid, remains a focal point for revenue projections.
Shares last traded at $29.65, up 1.8% on the day, after earlier hitting the 52-week high.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →